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Given that the pathophysiology of AMS remains unresolved, we propose that the broader view provided by global proteomics and other discovery-based strategies may provide novel insights into the etiology of AMS and identify new avenues for prevention or treatment of the condition.
MATERIALS AND METHODS
Overall study approach. Peripheral venous blood samples were collected and AMS symptoms evaluated under normoxic, normobaric conditions (1,609 m; barometric pressure ϭ 630 mmHg) 15 h [baseline (BL)] before, immediately prior to (0 h), and after 9 h of hypobaric hypoxia (4,875 m; barometric pressure ϭ 425 mmHg) in a hypobaric chamber. Immediately after "ascent" to 4,875 m, subjects completed four 30-min submaximal exercise bouts on a cycle ergometer at 50% of altitude-adjusted maximal oxygen uptake (V O2 max) with 15 min rest between each to increase the likelihood of developing AMS (46) . Subjects rested for the remainder of the hypobaric hypoxia exposure.
Subjects. Subjects included for analysis were 20 healthy volunteers (17 men and 3 women) living near Denver, Colorado (1,609 m). These individuals are a subset of 29 subjects who participated in a larger study of the pathophysiology of high-altitude headache and AMS (26, 51) . The subset of 20 subjects included here represent those individuals with the highest (top 10) and lowest (bottom 10) AMS scores after 9 h of hypobaric hypoxia, as previously described (26) . Despite reducing our overall sample size, this approach avoids the inclusion of subjects with ambiguous AMS status.
Subject recruitment, screening, and exclusion criteria are described elsewhere (52) . Briefly, screening procedures to assess general health status and to determine eligibility prior to participation included medical history, physical and neurological exam, standard blood and urine analysis, and a maximal exercise test. Volunteers were excluded if they had any health problems; an abnormal complete blood count, chemistry panel, or liver function results; pregnancy; history of migraine or head injury with loss of consciousness; mechanical limitations that prohibited exercise; claustrophobia; smoking; seizure; metal implants; regular consumption of prescription medications (with the exception of birth control pills for women); inability to reach a workload of least 200 W during the incremental exercise test; or altitude exposure greater than 2,500 m within 3 wk of study. Qualifying subjects provided written informed consent as approved by the Colorado Multiple Institutional Review Board before participation.
Evaluation of AMS status. To evaluate AMS status, subjects completed the self-reported sections of the Lake Louise Questionnaire (LLQ) prior to entering the chamber (BL and 0 h) as well as after 4 and 9 h of hypobaric hypoxia. Specifically, subjects were asked to quantify their degree of fatigue, headache, gastrointestinal upset, and dizziness on a four-point scale (0 ϭ no symptoms, 1 ϭ mild, 2 ϭ moderate, 3 ϭ severe). Subjects with a cumulative LLQ score Ն3 with headache on any one LLQ after ascent were defined as AMS susceptible (AMS), those with LLQ score Յ2 for all LLQs or without headache were defined as AMS resistant (AMS·R) (44) .
Sex and ethnicity was similar between AMS and AMS·R groups. Nearly all subjects were male (AMS 80%, AMS·R 90%), and the vast majority in each group were Caucasian or admixed Caucasian (e.g., Caucasian-Asian) (80% AMS, AMS·R 90%). The AMS group included one set of male siblings. Given the similarity of this distribution, we consider it unlikely that sex or ethnicity biased our findings.
Plasma collection and sample preparation. Blood samples were collected after Ն10 min in a semirecumbent position from an antecubital vein by routine venipuncture (BL) or an indwelling intravenous cannula (0 and 9 h) and then placed in EDTA-coated blood collection tubes. The plasma was separated by centrifugation and stored in 0.5-ml aliquots at Ϫ80°C until analysis.
Proteomic methods.
Prior to analysis the samples underwent a series of preprocessing steps to increase the probability of detecting hypoxia-induced protein expression changes in AMS and AMS·R. First, plasma samples collected from the 10 AMS subjects were pooled at each time point, resulting in three pooled samples for analysis (i.e., one at BL, 0 and 9 h). The same process was repeated for the 10 AMS·R subjects. Sample pooling is advantageous for exploratory studies aiming to identify common features of a population or disease group (e.g., AMS) because it reduces within-group biologic variation, making it easier to identify the most prominent differences between the specific populations of interest (16) . Existing literature indicates that for the majority of proteins data obtained from pooled samples is consistent with the mean of individual specimens that compose the pool (16) . Our workflow is shown in Fig. 1 .
Analysis of the human plasma proteome is notoriously challenging because of sample complexity (i.e., the human plasma proteome is composed of Ͼ10 6 unique protein molecules) and the vast range of protein concentrations within a given sample (99% of total plasma protein mass can be attributed to 30 highly abundant proteins) (4) . The presence of high-abundance proteins reduces the dynamic range of mass spectrometry analysis and thereby limits the identification of lower-abundance proteins. To address this challenge, a critical sample preparation step for plasma proteomic studies is to deplete or remove high-abundance proteins. After pooling the samples, the 14 most abundant proteins in human plasma (i.e., albumin, IgG, antitrypsin, IgA, transferrin, haptoglobin, fibrinogen, alpha 2-macroglobulin, alpha 1-acid glycoprotein, IgM, apolipoprotein AI, apolipoprotein AII, complement C3, and transthyretin) were removed using a standard, commercially available immunodepletion kit (Human 14 Multiple Affinity Removal System Spin Cartridges; Agilent Technologies, Santa Clara, CA) (55) . Although higher-abundance proteins may also be informative, their inclusion precludes a more refined assessment of protein composition. Each depleted sample (30 g) was then separated by molecular weight via 1D gel electrophoresis using a 4 -12% gradient polyacrylamide gel with a Bis-Tris buffer system (Nupage, Invitrogen, Carlsbad, CA). The entire lane for each sample was cut into ten bands, excised, washed, reduced, alkyated, and then digested overnight at room temperature with Fig. 1 . Our general proteomic workflow consisted of six primary steps, shown on the left. The specific method(s) used in our study for each of the six steps are illustrated on the right. Preprocessing steps included sample pooling by acute mountain sickness (AMS) status and time point and the removal of the 14 most abundant proteins in human plasma by immunodepletion. Protein depletion enhances the ability to identify low-abundance proteins. Each depleted sample was then separated by molecular weight via 1D gel electrophoresis. Protein profiles were generated for each sample using two different nano-liquid chromatography tandem mass spectrometry platforms for technical replication (i.e., a LTQ-XL linear ion trap mass spectrometer and a LTQ-FT ultra hybrid mass spectrometer). Chromatographic peak lists were generated from raw spectra and searched against primary sequence databases using an in-house Mascot server (Version 2.2.06, Matrix Science) for protein identification. Spectral counting (i.e., the number of spectra per protein normalized to the highest total number of assigned spectra in a run) was used for semiqualitative comparisons of changes in protein abundance with hypoxic exposure in AMS and AMS resistant (AMS·R).
sequencing grade modified Trypsin (Promega, Madison, WI) as previously described (39) .
Two protein profiles were generated for each sample using nanoliquid chromatography tandem mass spectrometry performed on 1) a LTQ-XL linear ion trap mass spectrometer and 2) a LTQ-FT ultra hybrid mass spectrometer (Thermo/Finnigan, Waltham, MA). We used two analytical platforms for technical replication.
For LTQ-XL mass spectrometry, 2 l of sample was injected onto a reverse-phase column (49) using a cooled (9°C) autosampler (AS-1, Eksigent, Dublin, CA) connected to a HPLC system run at 0.12 l/min before the split and ϳ400 nl/min postsplit (1100 Series; Agilent Technologies). A 60-min gradient of 12% to 30% acetonitrile (ACN) was used for peptide separation. The column effluent was coupled directly to the LTQ XL linear ion trap mass spectrometer with an in-house built nanospray ion source. Data acquisition was performed using Xcalibur (version 2.0.6) software. Precursor scans (MS) were sequentially recorded and followed by three collision-induced dissociation (CID) acquisitions (MS/MS). Singly charged ions were excluded from CID selection.
In addition, samples were analyzed on a LTQ-FT hybrid mass spectrometer. Peptide desalting and separation was achieved using a dual capillary/nanopump HPLC system (1200 Series; Agilent Technologies). On this system, 8 l of sample was loaded onto a trapping column (ZORBAX 300SB-C18, dimensions 5 ϫ 0.3 mm 5 m; Agilent Technologies) and washed with 5% ACN, 0.1% formic acid (FA) at a flow rate of 15 l/min for 5 min. At this time the trapping column was put online with the nanopump at a flow rate of 350 nl/min. A 55-min gradient from 12% ACN to 30% ACN was used to separate the peptides. Data acquisition on the LTQ-FT was performed as described above with the exception of utilizing four CID scans per precursor MS scan.
Data analysis and statistics. Independent sample t-tests or MannWhitney tests were used to identify differences in age, height, weight, and AMS scores between AMS and AMS·R subjects as appropriate. These data are expressed as the mean Ϯ SE. Criteria for significance was set a priori at two-tailed P Ͻ 0.05. Statistical analyses were conducted using SPSS 17.0 (Chicago, IL).
To assess protein components of each sample, the raw spectra generated from each mass spectrometer was used to create chromatographic peak lists. For data obtained by the LTQ-XL and LTQ-FT hybrid mass spectrometer an in-house script was used to create de-isotoped centroided peak lists from the raw spectra (.mgf format). These lists were then searched against primary sequence databases using an in-house Mascot server (Version 2.2.06, Matrix Science) for protein identification. For searches, MS/MS fragment ion mass tolerance was set to 0.6 Da, whereas the precursor MS tolerance was set to 0.6 Da and 10 ppm for the LTQ-XL and LTQ-FT, respectively. Trypsin specificity was used allowing for 1 missed cleavage. Met oxidation, protein N-terminal acetylation, and peptide N-terminal pyroglutamic acid formation were allowed for variable modifications while carbamidomethyl of Cys was set as a fixed modification. Samples were searched against all human entries in the SwissProt protein database (http://www.ebi.ac.uk/uniprot/).
All results were compiled using Scaffold (Version 2; Proteome Software) and exported into Microsoft Excel for analysis. Data are expressed as the number of assigned spectra ("spectral count") normalized to the highest total number of assigned spectra in a run, and the spectral count fold-change from preascent to 9 h. Spectral counting has been shown to be linearly correlated with protein abundance and is therefore used as a semiquantitative surrogate measure of protein abundance in cases where direct measures are not feasible (32) . Spectral counts were qualitatively compared across time in AMS and AMS·R subjects for data generated from both spectrometers.
To be considered a leading candidate, a protein had to meet specific criteria. First, it was required that the proteins' correlational analysis across time points obtained by LTQ-FT and the LTQ-XL were of similar magnitude and direction. Second, only protein expression changes that did not appear to be influenced by circadian effects were considered. To distinguish between the effects of hypobaric hypoxia vs. circadian rhythm, two preascent samples were collected. The first preascent sample (BL) was taken at ϳ4:00 PM one day prior to the hypoxic exposure, which temporally coincided with the 9-h time point of the hypoxic exposure (i.e., 4 pm the following day). The second preascent sample (0 h) was taken at ϳ7:00 AM, immediately prior to initiating the hypoxic exposure. If protein expression differences were identified between 0 and 9 h but not between BL and 9 h, it was assumed that the time of day rather than the hypoxic exposure itself was responsible and the protein was discarded from further consideration. For proteins that met these criteria, a threshold of Ն1.8-fold change from at least one preascent measurement to 9 h was used as a cut-off value for inclusion. To designate a protein as being distinct to AMS it was required that no or only minimal changes across time were apparent in AMS·R and vice versa for AMS·R distinct proteins.
Our exploratory analyses focused on the effect of hypobaric hypoxia on protein abundance in AMS and AMS·R subjects by comparing protein spectral counts between preascent and 9 h samples in AMS and AMS·R subjects.
Pathway analysis. Biological processes and functional enrichment of proteins associated with AMS and AMS·R were further categorized using the gene ontology and pathway tools available in the Database for Annotation, Visualization and Integrated Discovery (DAVID) bioinformatics resource (v6.7) (23). Unique AMS and AMS·R protein lists were introduced to DAVID using the appropriate identification symbol (i.e., UNIPROT_ID). To describe proteins based on their involvement in specific biologic processes we used the Gene Ontology function and selected the biologic process option (i.e., GOTERM_BP_FAT). Under the Pathway Analysis function, KEGG pathway was selected; parameters for inclusion were 1) a threshold count of two and 2) an EASE Score (i.e., a modified Fisher Exact P value) of Ͻ0.05. Using these classifications, we were better able to systematically organize proteins and pathways that are potentially relevant for AMS or human response to hypoxia more generally.
RESULTS AND DISCUSSION
Subject characteristics. Age, height, and weight were similar between AMS and AMS·R groups (27.8 Ϯ 2. Global proteomics responses. A total of 350 proteins or protein fragments were identified in the pooled plasma samples. Protein abundance changed in response to hypobaric hypoxia for 19 of the 350 proteins identified using our specified criteria (i.e., a 1.8-fold or greater difference between preascent and 9 h values). Of these 19 proteins, 8 were unique to AMS·R and 11 were unique to AMS (Table 1) . Using the DAVID bioinformatics program to detect the most prominent functional protein groups that differed in response to hypobaric hypoxia between AMS and AMS·R subjects, we identified that proteins involved in cellular redox homeostasis, in particular enzymatic antioxidant response, were elevated in AMS but not AMS·R (Table 2 ). In the sections to follow we discuss the potential relevance of this finding for human response to hypobaric hypoxia and AMS.
Enzymatic modifiers of redox status in AMS. Multiple mechanisms exist to protect against free radical-induced oxidative damage, including the nonenzymatic decomposition of oxidants by transition metals, removal by disproportionation reactions, and "capture" by antioxidant molecules and/or en-zymes. Enzymatic antioxidants are stimulated by oxidants and serve to regulate increasing levels of intracellular reactive oxygen species (ROS) in response to stressors such as hypobaric hypoxia. In this way, antioxidant enzymes protect against oxidative stress that results from an overabundance of oxidants relative to antioxidant capacity.
Dampening ROS production or activity reduces the potential for oxidant injury but also has potential adverse effects that may be of pathophysiological importance for AMS, such as interrupting oxidant-sensitive cell signaling and gene transcription (11, 24) . In the next few sections we attempt to integrate and reconcile our finding that enzymatic Two mass spectrometry platforms (LTQ-FT and LTQ-XL) and spectral counting was used to assess protein abundance prior to [baseline (BL) and 0 h] and during (9 h) a 10 h hypobaric hypoxia exposure. The fold-change of protein abundance between BL and 9 h and 0 to 9 h are shown for each platform. Blank fold-change values indicate that the protein was undetected at either BL or 0 but accompanied by 9 h values that were consistent with respect to direction and magnitude to observations made with the second platform (e.g., QSOX1 spectral counts using FT were 0 and 2.8 at BL and 9 h respectively, using LTQ values were 2.3 and 6.6 at 0 and 9 h, respectively).
antioxidant abundance is elevated in AMS with existing literature, indicating a positive relationship between oxidant production and AMS.
In AMS, three proteins most prominently known for their ability to modify redox status [i.e., peroxiredoxin-6 (Prdx-6), glutathione peroxidase (GPx), and sulfhydryl oxidase 1 (QSOX1)] increased approximately twofold after 9 h of hypobaric hypoxia compared with measurements made before ascent (Table 1 ). In contrast, in AMS·R no or minimal difference in Prdx-6 (no change) or GPx (0.4-fold increase) protein abundance was observed, whereas QSOX1 appeared to decline in response to hypobaric hypoxia (1.5-fold decrease). This is the first report of Prdx-6 or QSOX1 protein abundance at high altitude in humans acutely exposed to hypobaric hypoxia. With respect to GPx, our findings are supported by a report that hypoxic exposure (4 wk, 4,560 m) raises GPx activity in individuals from sea level (48) .
Peroxiredoxins and GPx protect against cellular oxidative stress and, through their regulation of hydrogen peroxide (H 2 O 2 ) levels, modulate redox-sensitive signaling cascades (19, 22, 54) . Prdx-6 is an oxidant-sensitive enzyme (13) and is distinguished from other members of the peroxiredoxin family, in part, by its dual peroxidase (i.e., oxidizes sn-2 fatty acyl group of phospholipids) and phospholipase A 2 (PLA 2 ) activity [i.e., hydrolyzes the sn-2 ester (alkyl) bond of phospholipids] (12, 18) . QSOX1 is a protein belonging to a family of flavin adenine dinucleotide (FAD)-dependent sulfhydryl oxidases that catalyze the oxidation of thiols to disulfides by reducing oxygen to H 2 O 2 . Despite producing H 2 O 2 , QSOX1 appears to protect against free radical-mediated apoptosis and downregulates cellular ROS levels (36, 42) . QSOX1 is also involved in oxidative protein folding, a redox-reaction-driven process that inserts disulfide bonds into reduced unfolded proteins to achieve functional protein conformation (14) .
Compensation for hypoxia-induced oxidant production in AMS?
One explanation for the rise in Prdx-6 [2.3-fold (LTQ-XL)], GPx [1.9-fold (FT)], and QSOX1 [2.8-fold (LTQ-XL)] abundance from preascent to 9 h in AMS relates to their role as redox-sensitive antioxidants. In other words, a hypoxia-associated rise in Prdx-6, GPx, and QSOX1 abundance may act to compensate for elevated hypoxia-induced oxidant production in individuals who develop AMS relative to those who do not. In support of this interpretation, hypoxia-induced oxidant production appears to parallel AMS severity. Specifically, using arterial-venous differences across the cerebral circulation, Bailey et al. (8) showed that cerebral oxidant output, particularly of lipid-based oxidants, increased during hypoxic exposure in humans and was positively associated with AMS score and hypoxia-induced headache. Similarly, hypoxia induces free radical production in the systemic circulation and cerebrospinal fluid (6, 7) and is associated with AMS (6) . Following this logic, elevated antioxidant enzyme levels in AMS may reflect a supracompensatory response to increased oxidant load. Correspondingly, the lack of change in Prdx-6 and GPx with hypobaric hypoxia in AMS·R may reflect comparatively reduced, but not absent, hypoxia-induced oxidant production relative to AMS.
Alternative mechanisms may also contribute to increased antioxidant enzyme production at high altitude in AMS. For example, in addition to being redox-sensitive, Prdx-6 expression is stimulated by nitric oxide (NO)-dependent mechanisms (15) . Although plasma NO and nitrate (NO 3 Ϫ ) decline in response to hypoxic exposure, plasma nitrite (NO 2 Ϫ ), total intraerythrocytic NO concentration and NO bound to hemoglobin rise in response to hypobaric hypoxia in individuals who develop AMS but not healthy controls (6) . We consider it possible that the rise in Prdx-6 observed in AMS could have been driven, in part, by NO-dependent mechanisms; however, further study is required to determine if this is the case. Exercise also stimulates Prdx-6 (35); however, this should have no bearing on the relationship between Prdx-6 and AMS we report given that all subjects underwent an identical exercise protocol during the study.
Limited efficacy of exogenous antioxidant therapy to prevent AMS. If exaggerated oxidant production plays a role in the pathophysiology of AMS attributable to oxidant injury, then it would be expected that AMS could be prevented or improved with antioxidant treatment. Thus far, however, exogenous antioxidant therapy as a strategy to treat or prevent AMS in humans has been ineffective (9) . Only one study with a comparatively small sample size (9 treated and 9 placebo controls) has shown modest beneficial effects (5). This does not, however, mean that oxidative stress is unimportant. It may be that oral antioxidant supplementation dosing or, in the case of our study, the heightened enzymatic antioxidant response in AMS was simply not sufficient to fully counter the level of oxidant production. In the case of antioxidant supplementation studies, the lack of efficacy may also be attributable, in part, to the exclusive use of dietary antioxidants (e.g., L-ascorbic acid). In contrast to dietary antioxidants that are stoichiometrically consumed, enzymatic antioxidants act as catalysts of dismutation reactions rather than as substrates and, as a result, have greater antioxidant capacity. In support of the hypothesis that preemptive enzymatic antioxidant therapy may prevent the onset of AMS, pharmacologic induction of the nuclear receptor factor (erythroid-derived 2)-related factor 2 (Nrf2), which regulates the majority of antioxidant genes including Prdx-1, reduces high altitude-induced cerebral vascular leak in rats (31) . To determine whether antioxidant insufficiency is respon- Proteins belonging to each gene ontology category and KEGG pathway are shown in italics. The % column refers to the proportion of proteins identified that fall within the specified pathway (e.g., 33% of "AMS·S" proteins were involved in complement and coagulation in the KEGG pathway database).
sible for the lack of efficacy it would be valuable to test whether the induction of enzymatic antioxidant production prior to hypoxic exposure effectively prevents the development of AMS.
Consequences of elevated enzymatic antioxidant status in AMS. Quenching oxidant activity is typically regarded as a beneficial outcome (i.e., inhibiting oxidative stress); however, reducing oxidant production or activity may have deleterious consequences such as interfering with oxidant-sensitive cell signaling and gene transcription including that of hypoxiainducible factor (HIF) 1␣, the master regulator of cellular responses to hypoxia (11, 24) . Although there remains some debate regarding the specific effects of redox status on HIF1␣ (e.g., HIF1␣ stabilization or destabilization), it is clear that both oxidants and enzymatic antioxidants modify HIF1␣ activity and, subsequently, influence the expression of HIFregulated genes (24, 38) . With respect to the role of enzymatic antioxidants, thioredoxin, a key antioxidant and regulator of cellular redox homeostasis, enhances HIF1 DNA binding in cell extracts and increases hypoxia-induced expression of a reporter construct containing the human erythropoetin HIF1 binding site in transfected HeLa cells (24) . It was recently proposed that the effect of redox status to modulate HIF1␣ activity is dependent, in part, on the duration of oxidant exposure such that ROS (H 2 O 2 ) induce HIF1␣ in the short term but repress HIF1␣ activity and the expression of prolylhydroxylase domain protein 2 (PHD2) after prolonged exposure (38) . In support, exposing human heptoma cell lines (HepG2 and Hep3B) to H 2 O 2 inhibits hypoxic-induction of erythropoietin (17, 24) . On the basis of these studies, we cautiously speculate that AMS individuals may overcompensate for hypoxia-induced oxidant production and that this may have negative downstream effects that are indirectly or directly related to AMS, perhaps by enhancing HIF1␣ activity (Fig. 2) . Further study is required to determine if this is the case.
PLA 2 activity: a link between Prdx-6 and AMS? An alternative or complementary explanation for the link between Prdx-6 and AMS relates to its PLA 2 activity, which liberates lysophopholipids and fatty acids (e.g., arachadonic acid) that are involved in the production of ROS and the regulation of proinflammatory responses (30) (Fig. 2) . In support of this possibility lipid-derived free radical production increases in the human brain during hypoxic exposure (8) and ischemic stroke (43), the latter being attributed to PLA 2 activation. Proinflammatory factors can also directly influence cerebral permeability and blood-brain barrier integrity by weakening the tight junctions between cerebral endothelial cells, thereby increasing the potential for vasogenic edema (50) . Although the topic of some debate, in light of the hypothesis that blood-brain barrier leak contributes to the etiology of AMS (25, 45) , the PLA 2 activity of Prdx-6 is particularly attractive. In support of the idea that inflammatory processes likely influence susceptibility to AMS, we previously showed that individuals who developed AMS had lower circulating levels of the anti-inflammatory factor IL1-RA after 4 and 9 h of hypobaric hypoxia compared with AMS·R and that pretreatment with acetazolamide prevented AMS and raised IL1-RA levels in AMS to those of AMS·R individuals (26) .
Limitations. Several considerations regarding the use of proteomic methods need to be addressed. One is the sample type chosen for analysis. Factors within the systemic plasma may not accurately represent the cerebral environment, but peripherally circulating proteins influence cerebral endothelial permeability (25) , suggesting their potential importance for AMS. A technical challenge of global proteomics is that the plasma proteome encompasses a larger number of proteins and a more dynamic concentration range than any other single human sample (4); this is prohibitive in that even after several depletion steps it is not possible to detect proteins of very low abundance that may be of importance.
With respect to our study design, both global proteomics and sample pooling have advantages and disadvantages. Performing proteomic studies on pooled as opposed to individual samples is supported by evidence that sample pooling reduces biologic variance between specimens in proteomic and microarray analyses (16, 21, 28, 41) and, consequently, facilitates the identification of the most robust differences between groups (16, 29) . A comprehensive evaluation of the effect of sample pooling for proteomic analysis demonstrated that, for the majority of proteins, data obtained for pooled samples accurately represents mean protein levels of the individual Fig. 2 . Potential relationship between elevated enzymatic antioxidant status and AMS using peroxiredoxin 6 (Prdx-6) as a model. There are several possible explanations for our observation that Prdx-6 is elevated by hypoxia in individuals who develop AMS during a hypobaric hypoxia exposure. Hypoxia increases oxidant and nitric oxide production, both of which are known to induce Prdx-6 expression. Prdx-6 is a bifunctional enzyme with both peroxidase and PLA2 activity. On one hand, increased peroxidase activity could be considered a beneficial, compensatory response to reduce increased oxidant production resulting from hypoxic exposure. On the other hand, oxidant species are pivotal players for numerous normal physiological responses such as cell signaling and the regulation of gene transcription, including that of hypoxia-inducible factor. In this sense, we speculate that overexpression of antioxidant enzymes may have deleterious consequences during hypoxic exposure. Prdx-6 may also be of pathologic importance to AMS because of its PLA2 activity, which liberates lysophopholipids and fatty acids (e.g., arachadonic acid) that are involved in the production of reactive oxygen species (ROS) and proinflammatory responses, both of have plausible biologic relationships to AMS.
samples that compose the pool rather than being skewed by one or two samples (16) . Although reducing biological variation masks unique features of individual samples that compose the sample pool, this strategy is advantageous when the research focus is to elucidate common features of a given population or disease group (28) , as was the case in our study. For this reason we did not analyze individual samples by mass spectrometry. However, as an internal validation, we confirmed with densitometry that our assessment of protein abundance by spectral counting for one of the proteins identified in our data set (i.e., actin) correlated well (correlation coefficient, 0.837) with values obtained by Western blot. Further supporting the validity of the proteomic methods we used, a recent paper confirmed that differentially expressed proteins identified by mass spectrometry (MALDI-TOF/MS) in high-altitude natives vs. sealevel controls were consistent with results obtained by Western blot and enzyme-linked immunosorbent assay (2) .
Summary. Our observation that exposure to hypoxia enhances enzymatic antioxidant systems in individuals who develop AMS questions the existing assumption that increased ROS production in AMS is pathological and predominantly related to oxidant injury and raises the possibility that quenching oxidant activity may have adverse effects that are of pathophysiological importance for AMS. In light of prior evidence that oxidative stress is linked to AMS, it is possible that increased enzymatic antioxidant response in AMS initially serves to counteract hypoxia-induced oxidant production. However, we propose that if this is a supracompensatory antioxidant enzyme response to ROS production, then there may be negative downstream effects related to oxidant signaling that are important for the pathophysiology of AMS. We point out several targets for future study to explain how overcompensation for hypoxia-induced oxidant production could become problematic with respect to AMS. Future experiments could include testing the effectiveness of manipulating enzymatic antioxidant status prior to hypoxic exposure, pharmacologically blocking overcompensation to hypoxia-induced oxidant production or targeting secondary oxidant messengers to determine whether the predominant connection between redox status and AMS is related to oxidant injury or signaling.
